For decades, intermittent preventive treatment in pregnancy (IPTp), with sulphadoxine-pyrimethamine (SP), has mitigated malaria-associated health risks, but concerns have been raised regarding accumulated <i>Plasmodium falciparum</i> dihydrofolate reductase (<i>dhfr</i>) and dihydropteroate synthase (<i>dhps</i>) mutations on the efficacy of SP. This evidence concerns the gene DHFR and malaria.